Allergan Acquires Motus Therapeutics for $200M

Oct 27, 2016

Xconomy

Allergan has announced it will acquire Boston-based Motus Therapeutics for $200 million.

Motus Therapeutics (formerly Rhythm Health) is a subsidiary of Boston-based Rhythm Holding Company.

Allergan had an option to acquire Motus based on a deal that Rhythm struck with Actavis, after Actavis merged with Allergan in 2015.

Allergan exercised its option after Motus released postive results from a Phase 2b study into its experimental drug, relamorelin. The drug aims to treat a type of gastroparesis related to diabetes, in which the stomach doesn’t empty into the intestine quickly enough, leading to abdominal pain, bloating, and vomiting.

Read the Xconomy coverage

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments